Chinese biopharmaceutical company Innovent Biologics, Inc (Innovent) (HKEX:01801) revealed on Tuesday the receipt of the US Food & Drug Administration (FDA) approval to initiate the US phase I clinical trial of its Anti-OX40 Monoclonal Antibody IBI101 in patients with advanced solid tumors.
In addition, Innovent is the first Chinese biopharmaceutical company to receive clinical trial approval from US FDA for an anti-OX40 monoclonal antibody.It has received US FDA's IND approvals for IBI308 (Sintilimab, an anti-PD-1 antibody) in January 2018 and IBI188 (an anti-CD47 antibody) in September 2018 respectively.
Following the US FDA approval, the company will initiate the US phase I clinical trial of IBI101 based on results from the China phase I study in patients with advanced solid tumours. IBI101 is its third molecule approved for clinical trials by US FDA.
IBI101, a recombinant fully human anti-OX40 (tumour necrosis factor receptor superfamily member 4) monoclonal antibody, was developed by the company and has independent intellectual property rights. Pre-clinical data confirm that IBI101 can significantly enhance the activation of effector T cells and mediate the clearance of regulatory T cells, thus inhibiting the growth of tumour cells. Agonistic OX40 candidates will be used in combination with other immunomodulation agents, including anti-PD-1 monoclonal antibody (IBI308) and other drugs in its R&D pipeline, to meet more unmet medical needs of cancer patients.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML